New Product Increases T-Cell Count in HIV/AIDS Patients
CLAREMORE, OK-Ives Health Company has released a brief summary of the touted Java project.
The project was a landmark AIDS study carried out by Slayton-Beedeen, MD, an immunologist and founder of the product T-Factor. Slayton-Beedeed worked with the World Health Organization (WHO) in Jakarta and Bangkok, testing HIV positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts. They administered T-Factor and found that new hormonal inhibitors of HIV might initiate profound suppression of HIV replication.
They gave these HIV-positive patients the drug and found 80% experienced documented decreases in HIV RNA and enhanced CD-4 counts within 24 weeks.
T-Factor costs less than $3 per day, in comparison to other HIV drug therapies that cost an estimated $80 daily.
New studies of the product are taking place in the US and in Europe.
For more information about the company or T-Factor, visit www.iveshelath.com.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
